| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.3 | 0.5 |
| Net income | 59.1 | -7.7 |
| EPS (diluted, $ a share) | $0.30 | $-0.04 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -43.5% |
|---|
10-Q filed with the SEC, NASDAQ: ABUS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Arbutus Biopharma Corp: key numbers
- Share price
- $4.05Close, Nov 17
- Market cap
- $621M
- Shares outstanding
- 153.29MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Arbutus Biopharma Corp
All →Arbutus Biopharma Investor Presentation
Arbutus Biopharma Corporation has posted an updated corporate presentation for Q4 2026 to its website and filed it with the SEC. The presentation outlines the company's strategic focus on developing a functional cure for chronic hepatitis B virus (HBV), including the clinical development of its lead candidate imdusiran. The filing serves as a routine update for investors regarding the company's pipeline, clinical trial designs, and future prospects.
Arbutus Biopharma Financial Results
Arbutus Biopharma reported Q3 2026 financial results, highlighting a strong cash position of $337.5 million following a $178.4 million settlement payment from Moderna. The company also announced expanded patent infringement litigation against Pfizer and BioNTech in Japan and Canada regarding its LNP technology.
- Term
- Q3 2026
“This has been a busy and productive quarter for the Arbutus team. I would like to congratulate our finance team, which successfully returned a substantial portion of Moderna’s first patent infringement payment to shareholders, and our R&D team, for achieving the lift of the 2023 U.S. FDA clinical hold on our oral PD-L1 inhibitor, AB-101, following a successful Phase 1 trial abroad.”
Lindsay Androski, President and CEO
Arbutus Biopharma Business Update
Arbutus Biopharma announced that the FDA has lifted the clinical hold on the Investigational New Drug (IND) application for AB-101, its oral PD-L1 inhibitor. The company is now authorized to resume clinical development of the candidate in the United States and is evaluating next steps for its continued development. AB-101 is being developed as a potential treatment for chronic hepatitis B virus (cHBV) infection.